Coloplast A/S (OTCMKTS:CLPBY – Get Free Report) announced its earnings results on Tuesday. The company reported $0.10 EPS for the quarter, beating analysts’ consensus estimates of $0.09 by $0.01, Zacks reports. Coloplast A/S had a net margin of 14.35% and a return on equity of 27.87%.
Coloplast A/S Price Performance
Shares of CLPBY traded up $0.07 during mid-day trading on Tuesday, hitting $6.40. The company’s stock had a trading volume of 11,909 shares, compared to its average volume of 584,723. The company has a current ratio of 1.30, a quick ratio of 0.81 and a debt-to-equity ratio of 1.50. Coloplast A/S has a 1-year low of $6.10 and a 1-year high of $10.03. The firm has a market capitalization of $14.42 billion, a P/E ratio of 23.70, a P/E/G ratio of 2.03 and a beta of 0.15. The firm has a 50-day simple moving average of $6.76 and a 200 day simple moving average of $8.00.
Analyst Upgrades and Downgrades
CLPBY has been the topic of several recent research reports. The Goldman Sachs Group cut Coloplast A/S from a “hold” rating to a “strong sell” rating in a research report on Tuesday, April 7th. Sanford C. Bernstein upgraded Coloplast A/S to a “hold” rating in a research note on Wednesday, January 28th. One investment analyst has rated the stock with a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Coloplast A/S currently has a consensus rating of “Reduce”.
Coloplast A/S Company Profile
Coloplast A/S is a global developer and manufacturer of medical devices and services focused on intimate healthcare. The company specializes in solutions designed to assist individuals with chronic medical conditions, aiming to improve quality of life through innovative products. Coloplast’s offerings span ostomy care, continence care, wound and skin care, and interventional urology, targeting patients who require long-term support and specialized treatments.
In its ostomy business, Coloplast provides pouches, skin barriers and accessories for patients who have had surgical procedures to divert bodily waste.
Read More
- Five stocks we like better than Coloplast A/S
- MP Materials Is Quietly Building a Rare Earth Powerhouse
- AI Demand Fuels Strong Q1 Earnings for Constellation Energy
- Sony’s $4 Billion Bet on Rock & Roll Royalties
- Ubiquiti’s Uptrend Can Continue, But Don’t Rush to Buy It
Receive News & Ratings for Coloplast A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coloplast A/S and related companies with MarketBeat.com's FREE daily email newsletter.
